Research · 9 min read
What a GLP-1 Program Should Actually Include
Almost every telehealth program can write a prescription. What separates them is everything around it — who you can reach, what happens when something goes wrong, and how much of it is written down before you pay.
Key takeaways
- The prescription has largely converged between programs; support, follow-up and written terms are where they differ.
- Ask who responds to a clinical question and within what window, and what the program tells you to do outside business hours.
- A program built around refills is different from one built around scheduled follow-up, and both market themselves similarly.
- For a compounded product, look for the named pharmacy and what documentation arrives — what a program will put in writing is itself information.
- Read cancellation, refund, commitment length and supply-interruption terms before entering a card, not after.
- A warning letter discloses; most concern marketing and labeling rather than the contents of a vial, and it is one input rather than a verdict.
The prescription is the easy part
By the time you are comparing programs, the thing they are selling has largely converged. The differences that matter show up after the first month, and they are mostly about support, transparency and what happens when something does not go to plan.
That is a useful reframe, because it changes what to look at while you are still choosing. A homepage is built to describe the first week. The questions worth asking are about month four.
What follows is a checklist of things to look for, written as things a program either publishes or does not. Every one of them is checkable before you enroll, which is the point of listing them.
Who you can actually reach, and how fast
The single most common complaint about telehealth in this category is not being able to reach anyone once the initial sale is done. It is worth testing before it matters.
Look for whether the program says who responds — a clinician, a coach, or a support agent — and whether those are different queues with different response times. Those are not the same thing and a program that blurs them is telling you something.
Look for a stated response window, and for whether any channel is synchronous. A message thread that answers in a few business days is fine for a scheduling question and unhelpful when a symptom is escalating.
And look for what happens outside business hours, and what the program tells you to do instead. A clear instruction to seek care elsewhere is a good answer. Silence is not.
Whether anyone is checking on you
A program built around refills is different from a program built around follow-up, and both exist under similar marketing.
Look for scheduled check-ins rather than only refill triggers. Look for whether the program describes what happens at a schedule increase, and whether anyone reviews how the previous step went before the next one.
Look for whether laboratory testing is arranged, mentioned, or left entirely to you. Programs differ substantially here and they generally say so somewhere, often in a details page rather than on the landing page.
And look for whether there is any pathway for the things around the medication — nutrition support, movement, and the muscle question that appetite suppression makes unavoidable. A program that has nothing to say about protein is describing half the treatment.
What is written down about the product
This is where programs separate most clearly, because it costs nothing to publish and some do not.
For a compounded product, the specific things to look for are whether the pharmacy is named, what the product actually is, and what its category means. Compounded and approved products are not the same legal object, and the difference is about oversight and accountability rather than a claim about quality.
Look for whether the program states what you receive and in what form, and whether instructions for use come with it. Look for whether a way to ask a question about the product itself exists, separate from a general support queue.
Where a program publishes none of this, that is information. It is not proof of anything about the product, and it does tell you what the program is willing to put in writing.
The commercial terms, before you enter a card
Read the terms on cancellation, refunds and plan length before enrolling, not after. This is the most common source of genuine anger in this category and it is entirely avoidable.
Look for whether a plan is a subscription and what the commitment is. Look for whether the advertised arrangement requires a longer term than the one presented first. Look for whether cancellation is self-service or requires contacting someone, and whether anything is refundable once shipped.
Look for what happens if you stop mid-plan, and for what happens if a product cannot be supplied. Programs that answer both in writing are unusual and worth noticing.
None of this is about the amount. It is about whether the arrangement is stated plainly enough that you could describe it to someone else accurately after reading it once.
Whether it works where you live, and stays working
Availability in this category is state by state, and a program serving most states does not necessarily serve yours.
Look for a stated list rather than an implication. And check it against where you actually are, which for people who move between states is a question with two answers.
Ask what happens if you relocate, because that is a real interruption people do not anticipate. Ask what happens if a product becomes unavailable, since supply in this category has not been uniformly stable.
Both are questions about continuity rather than about signup, which is exactly why they are worth asking during signup.
How to read an enforcement action or a regulatory letter
These exist in this space and they are worth understanding rather than reacting to.
A warning letter discloses something. The large majority concern marketing and labeling — how a product was promoted or presented — rather than the contents of a vial. It is not evidence that a medication is contaminated, ineffective or dangerous.
So the useful reading is specific: what was the letter actually about, and does it concern something that matters to you. A letter about promotional claims is a different object from a manufacturing finding, and treating them identically discards the information.
Weigh it as one input among many. It is a fact worth knowing and it is not, by itself, a reason to rule a program in or out.
The questions to ask before you pay
Ask who responds to a clinical question, and within what window. Ask what happens outside business hours.
Ask what follow-up is scheduled, what is reviewed before a schedule increase, and whether any laboratory testing is arranged.
Ask what the product is, which pharmacy prepares it if it is compounded, and what documentation comes with it.
Ask what the plan commits you to, how cancellation works, what is refundable, and what happens if supply is interrupted or you move.
A program that answers all of those in writing, before payment, has told you most of what you need. One that answers none of them has also told you something.
Frequently asked questions
What actually separates one GLP-1 telehealth program from another?
Rarely the prescription, and mostly everything around it. The differences that matter show up after the first month. Who you can reach and how quickly, and whether follow-up is scheduled or only triggered by refills. Whether anything reviews how a step went before the next one, and what the program will put in writing about the product and the terms. A homepage describes the first week. The questions worth asking before you enroll are about month four.
What should a program tell me about a compounded product?
At minimum, what the product is, what form it comes in, which pharmacy prepares it, and what documentation arrives with it. Compounded and approved products are different legal objects, and that difference is about oversight and accountability rather than a claim about quality in either direction. Where a program publishes none of this, that is not proof of anything about the product itself. It does tell you what the program is prepared to state in writing, which is a reasonable thing to weigh.
How do I judge the support before I have used it?
Look for specifics that are checkable in advance. Whether the program says who responds — a clinician, a coach, or a support agent — and whether those are separate queues with different response times. Whether a response window is stated at all. Whether any channel is synchronous, since a thread answering in several business days is fine for scheduling and unhelpful for an escalating symptom. And what the program tells you to do outside business hours, where a clear instruction to seek care elsewhere is a good answer and silence is not.
Does a warning letter mean I should avoid a company?
Not on its own. A letter discloses something, and the large majority in this space concern marketing and labeling — how a product was promoted or presented — rather than the contents of a vial. It is not evidence that a medication is contaminated, ineffective or dangerous. The useful reading is specific: what the letter was actually about, and whether that concerns something relevant to you. A letter about promotional claims is a different object from a manufacturing finding, and it is one input among many rather than a verdict.
What commercial terms should I read before enrolling?
Whether the plan is a subscription and what the commitment length is, since the arrangement presented first is not always the one advertised. Whether cancellation is self-service or requires contacting someone. What is refundable once something has shipped. What happens if you stop mid-plan. And what happens if a product cannot be supplied. Programs answering all of those in writing are less common than you would expect, and reading them before entering a card removes the most avoidable source of frustration in this category.
What questions matter about where I live?
Availability here is state by state, so look for a stated list rather than an implication that a program serves everyone. Check it against where you actually are, which is a question with two answers for anyone splitting time between states. Then ask two continuity questions during signup rather than after: what happens if you relocate, and what happens if a product becomes unavailable. Supply in this category has not been uniformly stable, and both interruptions are the kind people do not plan for.